1. | Jamsen K, Kirkpatrick C, Opoku N, Attah S, Awadzi K (Deceased), Kuesel AC, Olliaro P, Olipoh G, Ryg-Cornejo V, Tan B, Sullivan MT, Fleckenstein L, Rayner CR. Determining the Optimal Dose of Moxidectin for Onchocerciasis via Pharmacokinetic-Pharmacodynamic (PK-PD) Modelling of Data from Healthy Volunteers and Patients with Onchocerciasis. American Society of Tropical Medicine and Hygeine. Washington DC Nov 7, 2017. A762 |
2. | Milton P, Walker M, Kuesel AC, Opoku NO, Attah SK, Kanza E, Bakajika D, Howard H, Halleux CM, Rayner CR, Smith D, Pearce G, Sullivan MT, Basáñez MG. The potential for six-monthly mass administration of moxidectin to accelerate onchocerciasis elimination. American Scoiety of Tropical Medicine and Hygeine. Washington DC Nov 7, 2017. LB-5102 |
3. | Milton P, Walker M, Kuesel AC, Opoku NO, Attah SK, Kanza E, Bakajika D, Howard H, Halleux CM, Rayner CR, Smith D, Pearce G, Sullivan MT, Basáñez MG. Modelling alternative treatment strategies for onchocerciasis: moxidectin for control and elimination. American Scoiety of Tropical Medicine and Hygeine. Washington DC Nov 7, 2017. A-1800 |
4. | MCPA Steering Committee. The Australian Medical Countermeasures Consortium and Medical Countermeasures Products Australia (MCPA). 2014 MCMi Regulatory Science Symposium, FDA Headquarters, White Oak Campus, Silver Spring MD (June 2-3 2014). |
5. | Wu D, Chaiyakunapruk N, Pratoomsoot C, Lee K, Chong HY, Nelson NE, Smith PF, Kirkpatrick CM, Kamal M, Nieforth K, Dall G, · Toovey S, ·Kong DC, · Kamauu A, Rayner CR. Cost-Utility Analysis of Optimal Dosing of Oseltamivir Under Pandemic Influenza Using a Novel Approach: Linking Health Economics and Transmission Dynamic Models Value in Health 11/2014; 17(7):A807. |
6. | Wu D, Chaiyakunapruk N, Pratoomsoot C, Lee K, Chong HY, Nelson NE, Smith PF, Kirkpatrick CM, Kamal M, Nieforth K, Dall G, · Toovey S, ·Kong DC, · Kamauu A, Rayner CR. Oseltamivir use in an Influenza Outbreak: Linking Pharmacology to Pharmacoeconomics. IDWeek 2014 Meeting of the Infectious Diseases Society of America; 10/2014 |
7. | Patel K, Rayner CR, Giraudon M, Kamal MA, Morcos PN, Robson R, Kirkpatrick CM. Oseltamivir dosing optimisation in patients treated with automated peritoneal dialysis. Population Approach Group of Australia & New Zealand, Dunedin, New Zealand; 01/2014 |
8. | Smith PF, Kirkpatrick CM, Rayner CR Wu D, Chaiyakunapruk N, Pratoomsoot C, Lee K, Chong HY, Nelson NE, Nieforth K, Dall G, · Toovey S, ·Kong DC, Kamauu A, Kamal M. Estimating Health Outcomes of Antiviral Use in Influenza Outbreaks by Linking PK/PD and Epidemiology via a Transmission Dynamic Model: A Novel Approach. IDWeek 2014 Meeting of the Infectious Diseases Society of America; 10/2014 |
9. | Lefebvre E, Enejosa J, Béliveau M, Jomphe C, Marier JF, Rayner CR, Smith PF, Gathe J. Exposure-Response Relationship of Cenicriviroc with Week 24Virologic Outcomes in Treatment-Naïve HIV-1-Infected Adults with CCR5-Tropic Virus. 14th European AIDS conference, Brussels, Belgium, 16-19 Oct 2013 |
10. | Kamal M, Acosta E, Kimberlin D, Gibiansky L, Jester P, Niranjan V, Rath B, Clinch B, Sanchez P, Ampofo K, Whitley R, Rayner CR. Population pharmacokinetics define dosing recommendations of oseltamivir in neonates and infants with influenza. Options for the Control of Influenza VIII, Cape Town, South Africa, 5-10 Sep 2013 |
11. | Weber CS, Fukushima Y, Guenther A, Jiang Q, Kim S, Li R, Lim Y, Lu P, Peck R, Rayner CR, Zhai S. Ethnic sensitivity assessment during drug development: past, present and future in a large Pharmaceutical company. ASCPT 2012 |
12. | Rayner CR, Rath B, Brzostek J, Charoin-Pannier A, Chappey C, Abadir D, Wollenhaupt M, Niranjan V. The pharmacokinetics and safety of oseltamivir in infants <1 year with influenza. XIV International Symposium on Respiratory Viral Infections (ISRVI), Istanbul, Turkey, 23–26 March 2012 |
13. | Rath B, Rayner CR, Brzostek J, Charoin-Pannier A, Chappey C, Abadir D, Wollenhaupt M, Niranjan V. Clinical and virological response to oseltamivir in infants <1 year with influenza. XIV International Symposium on Respiratory Viral Infections (ISRVI), Istanbul, Turkey, 23–26 March 2012 |
14. | Rayner CR, Bulik CC, Kamal MA, Reynolds DK, Toovey S, Hammel JP, Smith PF, Bhavnani SM, Ambrose PG, Forrest A. Pharmacokinetic-Pharmacodynamic (PK-PD) Determinants of Oseltamivir Efficacy Using Data from Two Phase 2 Inoculation Studies. XIV International Symposium on Respiratory Viral Infections (ISRVI), Istanbul, Turkey, 23–26 March 2012 |
15. | Yang KH, Reddy M, Pamulapati C, Rayner CR, Forrest A. Development of a Pharmacokinetic Model for Oseltamivir in Ferrets Using Iterative Two-Stage Analysis. American College of Clinical Pharmacy Virtual Poster Symposium, May 22–24, 2012 |
16. | Brennan BJ, Cirrincione-Dall G, Morcos PN, Beryozkina A, Chappey C, Berns HK, Davies BE and Rayner CR. The safety, tolerability, and pharmacokinetics of oseltamivir following multiple intravenous infusions administered to healthy volunteers. XIII International Symposium on Respiratory Viral Infections (ISRVI), Rome, Italy, 13–16 March 2011 |
17. | Kamal M, Brennan B, Subramoney V, Morcos PN, Frey N, Rayner CR. Identification of new oral dose regimens for the neuraminidase inhibitor oseltamivir (Tamiflu®) in patients with moderate and severe renal impairment supported by a population pharmacokinetic approach. American Conference on Pharmacometrics (ACoP) 2011, San Diego, USA, 3–6 April 2011 |
18. | Davies B, Aceves Baldó P, Lennon-Chrimes S, Rayner CR. Safety, Tolerability and Pharmacokinetics of Intravenous Oseltamivir Phosphate in Healthy Volunteers: A Phase I Trial. XII International Symposium on Respiratory Viral Infections (2009) |
19. | Toovey S, Rayner CR, Prinssen EP, Chu T, Donner B, Dutkowski R, Sacks S, Solsky J, Small I, Reddy D. Post-marketing safety assessment of neuropsychiatric adverse event risk in patients with influenza treated with oseltamivir. International Symposium on Respiratory Viral Infections, Singapore, 28 February–2 March 2008 |
20. | Toovey S, Rayner CR, Prinssen EP, Chu T, Donner B, Thakrar B, Dutkowski R, Hoffmann G, Breidenbach A, Lindemann L, Boak L, Gieschke R, Sacks S, Solsky J, Small I, Reddy D. Neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Seasonal and Pandemic Influenza, Arlington, VA, USA, 18–20 May 2008. |
21. | Gieschke R, Rayner CR, Chanu P, Boak LM, Jonsson N. Population Pharmacokinetics of Oseltamivir when Co-Administered with Probenecid. X International Symposium on Respiratory Viral Infections, Singapore, 28 February–2 March (2008) |
22. | Gieschke R, Jonsson N, Boak L, Cameron J, Kinnersley N, Rayner CR. A dose prediction model for optimising use of oseltamivir against emerging pandemic strain of influenza. X International Symposium on Respiratory Viral Infections, Singapore, 28 February–2 March (2008) |
23. | Gieschke R, Dutkowski R, Smith J, Rayner CR. Similarity in the pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian children. Options for Influenza Conference, Toronto (2007) |
24. | Rayner CR, Andes D, Marchillo K, Conklin R, Stamstad T, Craig WA. Comparison of Fluoroquinolone (FQ) Dose effect Relations by Interval & FQ against Pseudomonas aeruginosa ATCC 27853 (PSA) in Neutropenic Murine-Thigh Infection Models. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA, Oct 2004 |
25. | Sudhakaran S, Rayner CR, Ghabrial H, Kong DCM, Gude NM, Angus PW, Nation RL. Placental Transfer (PT) of Indinavir (I) Modulated by P-glycoprotein (Pgp) 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA, Oct 2004 |
26. | Rayner CR, Dooley MJ, Nation RL. Inhibitory quotient variability should be considered if used to assess the potency of an anti-HIV-1 protease inhibitor regimen. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, USA, Sept 2003. (Abstract H-1997) |
27. | Tan E., Rayner C.R., Chapman C., Cranswick N. MIMS annual: How much can hospital pharmacists rely on it for information on paediatric dosing? Society of Hospital Pharmacists of Australia, 27th Federal Conference in Hobart, November, 2002. |
28. | Rayner C.R., Baddour L., Birmingham M.C., Norden C., and Schentag J.J. Linezolid in the treatment of osteromyelitis:Results from compassionate use experience. In Proceedings from 8th Western Pacific Congress on Chemotherapy and Infectious Diseases, Perth, 1st -5th Dec, 2002 (Abstract 184) |
29. | Rayner C.R., Baddour L., Birmingham M.C., Norden C., and Schentag J.J. Linezolid in the treatment of osteromyelitis:Results from compassionate use experience. In Annual Conference of the Australasian Pharmaceutical Science Association, Melbourne 8-11 December 2002 (Poster 63) |
30. | Huang P., Kong DCM., Sanip A, Rayner C.R., Hooi PY, Choo S, Tong N, Storey E, Ioannides-Demos L., and Krum H. Ambulatory Neurology Pharmacy Service – Key to provision of seamless pharmaceutical care. Society of Hospital Pharmacists of Australia, 27th Federal Conference in Hobart, November, 2001. |
31. | Birmingham MC, Rayner CR, Flavin SM, Meagher AK, Schentag J.J. Outcomes of Treating Patients with Malignancies and Significant, Resistant Gram-Positive Infections with Linezolid. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, Sept 2000 |
32. | Root JD, Birmingham MC, Rayner CR, Flavin SM, Schentag JJ. Results of Treating Patients with Significant, Resistant, Gram Positive, Intra-abdominal Infections with Linezolid. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, Sept 2000. |
33. | Birmingham MC, Zimmer GS, Flavin S, Rayner CR, Welch KE, Smith PF, Root JD, Meagher AK, Schentag JJ. Results of Treating Bacteremic Patients with Linezolid in a Compassionate Use Trial for Resistant, Gram-Positive Infections. 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones (ICMAS-KO), Seville, Spain Jan 2000 |
34. | Smith PF, Forrest A, Adams JM., Rayner CR, Wood R, Proulx L. Integrating Viral Dynamics and Pharmacokinetics of DOTC in HIV Positive , Antiretroviral Naïve Patients. XIII International AIDS Conference, Durban, South Africa, July, 2000. |
35. | Forrest A, Smith PF, Rayner CR. Pharmacokinetic and Dynamic Modelling of “Proof of Concept” Trial Data. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, Sept 2000. |
36. | Forrest A, Rayner CR, Meagher AK, Birmingham MC, Schentag JJ. Pharmacostatistical Modelling of Effects of Linezolid on Platelets in Seriously-Ill Patients. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, Sept 2000. |
37. | Forrest A, Rayner CR, Meagher AK, Birmingham MC, Schentag JJ. Population PK/PD/TK of Linezolid: Application to Dose Optimization. Population PK/PD Symposium. Montreal, Canada, October 2000. |
38. | Rayner C.R., Forrest A., Meagher A.K., Birmingham M.C. Schentag J.J. Population Pharmacodynamics of Linezolid in Seriously-Ill Adult Patients from a Compassionate-Use Protocol. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, Sept 2000. |
39. | Meagher A.K., Forrest A., Rayner C.R., Birmingham M.C. Schentag J.J. Population Pharmacokinetics of Linezolid in Seriously-Ill Adult Patients from a Compassionate-Use Protocol. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, Sept 2000. |
40. | Birmingham M.C., Zimmer G.S., Flavin S., Rayner C.R., Welch K.E., Smith P.F., Root J.D., Meagher A., Schentag J.J. Results of Treating Bacteremic Patients with Linezolid in a Compassionate Use Trial for Resistant, Gram-Positive Infections. 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones (ICMAS-KO), Seville, Spain Jan 2000. |
41. | Birmingham M.C., Zimmer G.S., Flavin S., Rayner C.R., Welch K.E., Smith P.F., Root J.D., Meagher A., Schentag J.J. Results of Treating Bacteremic Patients with Linezolid in a Compassionate Use Trial for Resistant, Gram-Positive Infections. 37th Annual Meeting of the Infectious Diseases Society of America (IDSA), Philadelphia, PA, Nov 1999. |
42. | Birmingham M.C., Zimmer G.S., Hafkin B., Todd M., Batts D.H., Wilks N.E., Flavin S., Rayner C.R., Schentag J.J. Outcomes with Linezolid from an Ongoing Compassionate Use Trial of Patients with Significant, Resistant, Gram Positive Infections. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA Sept 1999. |
43. | Birmingham M.C., Zimmer G.S., Hafkin B., Todd M., Batts D.H., Wilks N.E., Flavin S., Rayner C.R., Schentag J.J. Linezolid given Intravenously or Orally for Compassionate Use in Patients with Significant, Resistant, Bacterial Infections – Preliminary Results. 21st International Congress of Chemotherapy (ICC), Birmingham, UK. Journal of Antimicrobial Chemotherapy July 1999;44 (suppl A):112. |
44. | Birmingham M.C., Zimmer G.S., Hafkin B., Todd M., Batts D.H., Wilks N.E., Flavin S., Rayner C.R., Schentag J.J. Use of Linezolid in Critical Care Patients with Resistant Gram Positive Infections. Critical Issues in Respiratory and Critical Care Medicine Science and Technology Symposium, St. Jean Cap Ferrat, France June 7-9, 1999. |
45. | Birmingham M.C., Zimmer G.S., Hafkin B., Todd M., Batts D.H., Wilks N.E., Flavin S., Rayner C.R., Schentag J.J. Interim Results from a Linezolid Compassionate Use Trial in Patients with Significant, Resistant, Bacterial Infections. Gram Positive Infections in Humans, The Capital Hill Washington DC, March 26-27, 1999. |
46. | Rayner C., Brien J., Ioannides-Demos L.L., Liolios L., and Spicer, W. J. The Effect Altering Rate of Clearance has on the Pharmacodynamics of Gentamicin Against Enterobacter cloacae. Australasian Society of Clinical and Experimental Toxicologists, Annual Meeting, December, 1996. |
47. | Rayner C., Brien J., Ioannides-Demos L.L., Liolios L., and Spicer, W. J. Pharmacokinetic and Pharmacodynamic Considerations of Gentamicin Against Enterobacter cloacae. Society of Hospital Pharmacists of Australia, Victorian State Conference, November 15-17, 1996. |
48. | Rayner C., Ioannides-Demos L., Vujovic O., Spicer W.J., Spelman D., Tong N and Krum H. A drug use evaluation of vancomycin at a major teaching hospital. Society of Hospital Pharmacists of Australia, 23rd Federal Conference in Adelaide, November, 1997. |